These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
944 related articles for article (PubMed ID: 24885062)
1. Analyses of clinicopathological, molecular, and prognostic associations of KRAS codon 61 and codon 146 mutations in colorectal cancer: cohort study and literature review. Imamura Y; Lochhead P; Yamauchi M; Kuchiba A; Qian ZR; Liao X; Nishihara R; Jung S; Wu K; Nosho K; Wang YE; Peng S; Bass AJ; Haigis KM; Meyerhardt JA; Chan AT; Fuchs CS; Ogino S Mol Cancer; 2014 May; 13():135. PubMed ID: 24885062 [TBL] [Abstract][Full Text] [Related]
2. Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF wild-type colorectal cancers. Imamura Y; Morikawa T; Liao X; Lochhead P; Kuchiba A; Yamauchi M; Qian ZR; Nishihara R; Meyerhardt JA; Haigis KM; Fuchs CS; Ogino S Clin Cancer Res; 2012 Sep; 18(17):4753-63. PubMed ID: 22753589 [TBL] [Abstract][Full Text] [Related]
3. TGFBR2 and BAX mononucleotide tract mutations, microsatellite instability, and prognosis in 1072 colorectal cancers. Shima K; Morikawa T; Yamauchi M; Kuchiba A; Imamura Y; Liao X; Meyerhardt JA; Fuchs CS; Ogino S PLoS One; 2011; 6(9):e25062. PubMed ID: 21949851 [TBL] [Abstract][Full Text] [Related]
4. Prognostic role of PIK3CA mutation in colorectal cancer: cohort study and literature review. Liao X; Morikawa T; Lochhead P; Imamura Y; Kuchiba A; Yamauchi M; Nosho K; Qian ZR; Nishihara R; Meyerhardt JA; Fuchs CS; Ogino S Clin Cancer Res; 2012 Apr; 18(8):2257-68. PubMed ID: 22357840 [TBL] [Abstract][Full Text] [Related]
5. Associations between colorectal cancer molecular markers and pathways with clinicopathologic features in older women. Samadder NJ; Vierkant RA; Tillmans LS; Wang AH; Weisenberger DJ; Laird PW; Lynch CF; Anderson KE; French AJ; Haile RW; Potter JD; Slager SL; Smyrk TC; Thibodeau SN; Cerhan JR; Limburg PJ Gastroenterology; 2013 Aug; 145(2):348-56.e1-2. PubMed ID: 23665275 [TBL] [Abstract][Full Text] [Related]
6. Clinicopathological features of CpG island methylator phenotype-positive colorectal cancer and its adverse prognosis in relation to KRAS/BRAF mutation. Lee S; Cho NY; Choi M; Yoo EJ; Kim JH; Kang GH Pathol Int; 2008 Feb; 58(2):104-13. PubMed ID: 18199160 [TBL] [Abstract][Full Text] [Related]
7. Vitamin D receptor expression is associated with PIK3CA and KRAS mutations in colorectal cancer. Kure S; Nosho K; Baba Y; Irahara N; Shima K; Ng K; Meyerhardt JA; Giovannucci EL; Fuchs CS; Ogino S Cancer Epidemiol Biomarkers Prev; 2009 Oct; 18(10):2765-72. PubMed ID: 19789368 [TBL] [Abstract][Full Text] [Related]
8. CDK8 expression in 470 colorectal cancers in relation to beta-catenin activation, other molecular alterations and patient survival. Firestein R; Shima K; Nosho K; Irahara N; Baba Y; Bojarski E; Giovannucci EL; Hahn WC; Fuchs CS; Ogino S Int J Cancer; 2010 Jun; 126(12):2863-73. PubMed ID: 19790197 [TBL] [Abstract][Full Text] [Related]
9. Association between molecular subtypes of colorectal cancer and patient survival. Phipps AI; Limburg PJ; Baron JA; Burnett-Hartman AN; Weisenberger DJ; Laird PW; Sinicrope FA; Rosty C; Buchanan DD; Potter JD; Newcomb PA Gastroenterology; 2015 Jan; 148(1):77-87.e2. PubMed ID: 25280443 [TBL] [Abstract][Full Text] [Related]
10. A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer. Kawazoe A; Shitara K; Fukuoka S; Kuboki Y; Bando H; Okamoto W; Kojima T; Fuse N; Yamanaka T; Doi T; Ohtsu A; Yoshino T BMC Cancer; 2015 Apr; 15():258. PubMed ID: 25886136 [TBL] [Abstract][Full Text] [Related]
11. PIK3CA activating mutation in colorectal carcinoma: associations with molecular features and survival. Rosty C; Young JP; Walsh MD; Clendenning M; Sanderson K; Walters RJ; Parry S; Jenkins MA; Win AK; Southey MC; Hopper JL; Giles GG; Williamson EJ; English DR; Buchanan DD PLoS One; 2013; 8(6):e65479. PubMed ID: 23785428 [TBL] [Abstract][Full Text] [Related]
12. Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum. Yamauchi M; Morikawa T; Kuchiba A; Imamura Y; Qian ZR; Nishihara R; Liao X; Waldron L; Hoshida Y; Huttenhower C; Chan AT; Giovannucci E; Fuchs C; Ogino S Gut; 2012 Jun; 61(6):847-54. PubMed ID: 22427238 [TBL] [Abstract][Full Text] [Related]
13. SMO expression in colorectal cancer: associations with clinical, pathological, and molecular features. Li T; Liao X; Lochhead P; Morikawa T; Yamauchi M; Nishihara R; Inamura K; Kim SA; Mima K; Sukawa Y; Kuchiba A; Imamura Y; Baba Y; Shima K; Meyerhardt JA; Chan AT; Fuchs CS; Ogino S; Qian ZR Ann Surg Oncol; 2014 Dec; 21(13):4164-73. PubMed ID: 25023548 [TBL] [Abstract][Full Text] [Related]
14. Insulin-like growth factor 2 messenger RNA binding protein 3 (IGF2BP3) is a marker of unfavourable prognosis in colorectal cancer. Lochhead P; Imamura Y; Morikawa T; Kuchiba A; Yamauchi M; Liao X; Qian ZR; Nishihara R; Wu K; Meyerhardt JA; Fuchs CS; Ogino S Eur J Cancer; 2012 Dec; 48(18):3405-13. PubMed ID: 22840368 [TBL] [Abstract][Full Text] [Related]
15. High resolution melting analysis of KRAS, BRAF and PIK3CA in KRAS exon 2 wild-type metastatic colorectal cancer. Guedes JG; Veiga I; Rocha P; Pinto P; Pinto C; Pinheiro M; Peixoto A; Fragoso M; Raimundo A; Ferreira P; Machado M; Sousa N; Lopes P; Araújo A; Macedo J; Alves F; Coutinho C; Henrique R; Santos LL; Teixeira MR BMC Cancer; 2013 Apr; 13():169. PubMed ID: 23548132 [TBL] [Abstract][Full Text] [Related]
16. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial. Tabernero J; Lenz HJ; Siena S; Sobrero A; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Yoshino T; Goldberg RM; Sargent DJ; Wagner A; Laurent D; Teufel M; Jeffers M; Grothey A; Van Cutsem E Lancet Oncol; 2015 Aug; 16(8):937-48. PubMed ID: 26184520 [TBL] [Abstract][Full Text] [Related]
17. Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy? Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group Genet Med; 2013 Jul; 15(7):517-27. PubMed ID: 23429431 [TBL] [Abstract][Full Text] [Related]
18. Prognostic significance and molecular associations of 18q loss of heterozygosity: a cohort study of microsatellite stable colorectal cancers. Ogino S; Nosho K; Irahara N; Shima K; Baba Y; Kirkner GJ; Meyerhardt JA; Fuchs CS J Clin Oncol; 2009 Sep; 27(27):4591-8. PubMed ID: 19704056 [TBL] [Abstract][Full Text] [Related]
19. Mutations in both KRAS and BRAF may contribute to the methylator phenotype in colon cancer. Nagasaka T; Koi M; Kloor M; Gebert J; Vilkin A; Nishida N; Shin SK; Sasamoto H; Tanaka N; Matsubara N; Boland CR; Goel A Gastroenterology; 2008 Jun; 134(7):1950-60, 1960.e1. PubMed ID: 18435933 [TBL] [Abstract][Full Text] [Related]
20. BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer: primary or secondary genetic events in colorectal carcinogenesis? Velho S; Moutinho C; Cirnes L; Albuquerque C; Hamelin R; Schmitt F; Carneiro F; Oliveira C; Seruca R BMC Cancer; 2008 Sep; 8():255. PubMed ID: 18782444 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]